Home Featured Page 244

Featured

Latest

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference

Weekly Psychedelic Policy Briefing: September 30th, 2026

Bright Minds Biosciences Provides Scientific Update

Psychedelics: Past, Present, Future – Webinar

Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent...

Are Prodrugs the Next Wave of Psychedelic Drug Development?

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a...

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in...

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine)...

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved...

PT263 – Michelle Janikian – 920: The Magic Mushroom Holiday

Beckley Psytech announces first patient has received low-dose psilocybin in world-first...

EDITOR PICKS

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference

Weekly Psychedelic Policy Briefing: September 30th, 2026

Bright Minds Biosciences Provides Scientific Update

Psychedelics: Past, Present, Future – Webinar

Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent...

Are Prodrugs the Next Wave of Psychedelic Drug Development?

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a...

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in...

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine)...

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved...

PT263 – Michelle Janikian – 920: The Magic Mushroom Holiday

Beckley Psytech announces first patient has received low-dose psilocybin in world-first...

EDITOR PICKS

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY